Form 4: Dyne Therapeutics Director Dirk Kersten Reports Stock Sales

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) stock through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Dirk Kersten, a director of Dyne Therapeutics, reported the sale of common stock on August 8th and 9th, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (FCF IV) on April 9, 2024.
• On August 8, 2024, Kersten sold 6,377 shares at a weighted average price of $40.74, 16,357 shares at a weighted average price of $42.97, and 68,936 shares at a weighted average price of $42.87.
• On August 9, 2024, Kersten sold 50,736 shares at a weighted average price of $42.55, 40,268 shares at a weighted average price of $43.44, and 1,160 shares at a weighted average price of $44.04.
• Following these transactions, Kersten indirectly beneficially owns 6,232,959 shares through FCF IV and 1,428,571 shares through Forbion Growth Opportunities Fund II Cooperatief U.A. (FGO II).
• Kersten disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock sales by a director. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of stock sales by a company insider. Such transactions are common and can be driven by various personal financial planning reasons. The use of a pre-arranged Rule 10b5-1 trading plan suggests the sales were planned in advance and not based on any specific non-public information.

Comparison to Industry Standards

• Insider selling is a common occurrence in publicly traded companies, and the reported transactions are not unusual in terms of volume or price range.
• Similar filings are regularly made by directors and officers of comparable biotechnology companies such as Sarepta Therapeutics (SRPT) and BioMarin Pharmaceutical (BMRN).
• The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading, aligning with industry best practices.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider trading.
• The transactions are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates